a mature man conducting a seminar with the aid of a large screen displaying graphs and images of the earth.

The signatories to the arrangement, who will continue to remain independent of one another, are:

  • National Institute for Health and Care Excellence (NICE)

  • Canadian Agency for Drugs and Technologies in Health (CADTH)

  • Australian Government Department of Health and Aged Care

  • Healthcare Improvement Scotland

  • Health Technology Wales

  • All Wales Therapeutics & Toxicology Centre

This arrangement will allow the partners to work together on shared priorities to identify solutions to some of the common challenges they face.

Five initial priority areas have been agreed. These are:


Partners will share information about their work in COVID 19 how they are working with regulators, the prioritisation of topics, management of medicines with no marketing authorisation, planning for HTAs, and approaches to economic modelling.

Future-proofing of HTA systems

Partners will exchange ideas on how HTA processes could better anticipate technological and methodological challenges before they become issues for HTA and work together on scientific and methodological topics to address challenges.

Collaborating with regulators

Partners will explore implementing joint approaches to engaging with the regulatory agencies in the UK, Canada, and Australia to identify and progress opportunities to improve HTA and regulatory collaboration.

Work-sharing and efficiency gains

Partners will explore the feasibility of recognising or using each other’s HTA information and explore running a pilot for a joint clinical assessment.

Digital and Artificial Intelligence

Partners will share information about developments in the evaluation of digital health technologies, including technologies that involve artificial intelligence.

Working groups, aligned to the priority areas, will meet quarterly to review progress and discuss activities in their area. An annual meeting of all partner organisations will be held to review all activities and to realign where appropriate the developing areas of collaboration.

The partnership could be expanded to include other HTA bodies in the future, subject to the agreement of existing members, with the signed agreement reviewed after two years.

After years of successful informal collaboration, I am excited that we have now formalised our partnership with key members of the global HTA community, for the benefit of patients, the NHS, and the life sciences.

We share many of the opportunities and challenges that major developments in science and health care are presenting to us. By working together we will be able to anticipate, recognise, and responds to these. Sharing and developing solutions that work for all we serve.

While NICE remains independent, we know that working together will make us stronger, keeping us at the forefront of health technology assessment, and that can only benefit all our organisations and the people we serve.

Sign up for our newsletters and alerts

Keeping you up to date with important developments at NICE.